Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Placebo Effect01:54

The Placebo Effect

6.2K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.2K
Hindsight Biases01:12

Hindsight Biases

3.4K
Hindsight bias leads you to believe that the event you just experienced was predictable, even though it really wasn’t. In other words, you knew all along that things would turn out the way they did. Can you relate this to the phrase "Hindsight is 20/20" now? 
3.4K
Framing Effects03:26

Framing Effects

7.4K
Information is everywhere and its presentation—such as how and when items are presented—can impact our perceptions and decisions surrounding the info. This broad concept umbrellas framing effects—influences that occur due to the way information is framed in its appearance, whether it’s purely the order or the specific wording of a message. Let’s take a look at numerous ways in which two versions of something can objectively say the same thing, yet we respond in...
7.4K
Drug Therapy01:28

Drug Therapy

45
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
45
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

49
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
49
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

44
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
44

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correspondence: "Electrocardiography in a Patient with Deep Brain Stimulation".

Annals of Indian Academy of Neurology·2026
Same author

A Rare Case of Spinocerebellar Ataxia 50: The First Reported Case from the Indian Subcontinent with a Review of the Literature.

Annals of Indian Academy of Neurology·2026
Same author

Correction: Deep brain stimulation for Parkinson's disease in India: an expert consensus on availability, affordability, and eligibility by the Parkinson's research alliance India (PRAI).

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Association of Bassoon (BSN) Gene Mutations With Gait and Motor Impairments in Parkinson's Disease.

The European journal of neuroscience·2026
Same author

Deep brain stimulation for Parkinson's disease in India: an expert consensus on availability, affordability, and eligibility by the Parkinson's research alliance India (PRAI).

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Comprehensive Rehabilitation in a Child with Joubert Syndrome: A Case Report.

Progress in rehabilitation medicine·2026
Same journal

Hepatitis B Infection-Associated Aortoarteritis.

Annals of Indian Academy of Neurology·2026
Same journal

Correspondence- Muscle Magnetic Resonance Imaging Phenotyping and Pattern Recognition in Genetically Confirmed Myopathies: A Large-Cohort Study from the Indian Subcontinent.

Annals of Indian Academy of Neurology·2026
Same journal

STAC3-Related Congenital Myopathy (CMYP13) in an Adult Indian Patient: Expanding the Geographic Spectrum to India.

Annals of Indian Academy of Neurology·2026
Same journal

A Prospective Study on Autonomic Functions in Idiopathic Inflammatory Myopathies: The AFIIM Study.

Annals of Indian Academy of Neurology·2026
Same journal

Magnetic Resonance Imaging Findings During Encephalopathic Crisis in Glutaric Aciduria Type 1: Expanding the Radiologic Phenotype.

Annals of Indian Academy of Neurology·2026
Same journal

Thyroid Function and Cognitive Health in Older Adults: Insights from the LASI-DAD Study.

Annals of Indian Academy of Neurology·2026
See all related articles

Related Experiment Video

Updated: Jul 9, 2025

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

3.1K

Tofersen: Silver Lining or Hyperbole??

Tanushree Chawla1, Vinay Goyal1

  • 1Department of Neurology, Institute of Neurosciences, Medanta, The Medicity, Gurugram, Haryana, India.

Annals of Indian Academy of Neurology
|November 29, 2023
PubMed
Summary
This summary is machine-generated.

Tofersen is the first gene therapy approved for Amyotrophic Lateral Sclerosis (ALS) that targets SOD1 gene mutations. While it effectively lowers disease biomarkers, clinical improvement was not statistically significant.

Keywords:
Amyotrophic lateral sclerosisSOD1-related ALSTofersengene therapy

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

5.8K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Experiment Videos

Last Updated: Jul 9, 2025

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

3.1K
The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

5.8K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options.
  • Current FDA-approved drugs offer only modest delays in disease progression.
  • Genetic mutations, such as those in the SOD1 gene, account for some ALS cases.

Purpose of the Study:

  • To discuss the development and approval process of Tofersen, the first gene-based therapy for ALS.
  • To review Tofersen's mechanism of action in targeting SOD1-related ALS.

Main Methods:

  • Tofersen, an antisense oligonucleotide, targets SOD1 messenger RNA to reduce toxic protein production.
  • Evaluation of Tofersen's impact on SOD1 protein levels and neurofilament light chain (NfL) concentrations.
  • Assessment of clinical efficacy and safety during the drug's development and approval pathway.

Main Results:

  • Tofersen demonstrated a reduction in SOD1 concentrations in patients with SOD1-ALS.
  • A decrease in neurofilament light chain (NfL) levels, a biomarker for neurodegeneration, was observed.
  • Despite biomarker changes, Tofersen did not show statistically significant clinical improvement in the studied population.

Conclusions:

  • Tofersen represents a significant advancement as the first gene therapy approved for a subset of ALS patients.
  • The drug's ability to lower specific biomarkers suggests a biological effect on the disease process.
  • Further research may be needed to fully elucidate Tofersen's clinical benefit and its role in ALS management.